Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Atopic Dermatitis

Therapeutic area intelligence for Atopic Dermatitis with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 9
Catalysts: 0
Companies: 4

Companies

Apogee Therapeutics →

Bambusa Therapeutics →

Assets

Abrocitinib →

Dermatology →

ivarmacitinib →

Recent signals(9)

July 17, 2026

Ivarmacitinib shows early response linked to long-term efficacy in atopic dermatitis

A post hoc analysis of a phase-III trial indicates that early response to ivarmacitinib correlates with long-term efficacy in treating moderate-to-severe atopic dermatitis.

CompetitiveJuly 15, 2026

Benefit-risk assessment of dupilumab vs upadacitinib in atopic dermatitis

The Heads Up trial provides a structured benefit-risk assessment comparing dupilumab and upadacitinib for moderate-to-severe atopic dermatitis.

ClinicalJuly 13, 2026

Phase 1 Study of BBT001 in Atopic Dermatitis Patients Initiated by Bambusa Therapeutics

Bambusa Therapeutics has initiated Phase 1 trial of BBT001 in healthy volunteers and adult patients with moderate to severe Atopic Dermatitis.

ClinicalJuly 12, 2026

GX03 Shows Promise in Reducing Severity of S. aureus-Induced Dermatitis in Murine Model

The study evaluates the efficacy of GX03, an extended-release topical polyhexanide formulation, in a murine model of Staphylococcus aureus-induced dermatitis.

StrategyJuly 9, 2026

Abrocitinib shows sustained disease control in atopic dermatitis post-treatment

The study evaluated off-treatment disease control in patients who received abrocitinib 200 mg for 12 weeks, showing promising results.

ClinicalJuly 6, 2026

Study on Eczema Treatments and Skin Bacteria Launches

A new clinical trial is investigating the effects of eczema treatments on skin bacteria in patients with moderate to severe atopic dermatitis.

ClinicalJuly 3, 2026

Apogee Therapeutics initiates long-term safety study for APG777 in atopic dermatitis

Apogee Therapeutics is conducting a long-term safety and efficacy study for APG777 in patients with moderate-to-severe atopic dermatitis.

CompetitiveJune 26, 2026

AbbVie Trials Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Dupilumab Inadequate Responders

A new clinical trial is evaluating upadacitinib in adults with moderate-to-severe atopic dermatitis who have not responded adequately to dupilumab.

RegulatoryJune 16, 2026

FDA approves Lilly's EBGLYSS® for atopic dermatitis with unique dosing regimen

Lilly's EBGLYSS® (lebrikizumab-lbkz) is now approved for a maintenance dose every eight weeks, requiring only six injections per year.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.